Introduction: Most patients with lung cancer are elderly and poorly represented in randomized clinical trials. They are often undertreated because of concerns about their ability to tolerate aggressive treatment. We tested the hypothesis that elderly patients undergoing definitive lung radiation might tolerate treatment differently than younger patients.
Introduction
Cancer is a disease of the elderly, with more than 60% of malignancies diagnosed in men and women older than 65 years. 1, 2 As the elderly population in the United States continues to increase, the cancer burden will escalate as well. It is estimated that from 2010 to 2030, there will be a 45% increase in the overall cancer incidence that will be disproportionately accounted for by the elderly population. 3 However, elderly patients are poorly represented in the clinical trials that have defined the standard of care for cancer treatment. There is a significant gap in our understanding of the risks and benefits of managing elderly patients with cancer with standard treatment regimens.
Lung cancer is the leading cause of cancer death for both men and women in the United States. 4 More than 65% of patients in whom lung cancer is diagnosed are older than 65 years. 5 Paradoxically, the average median age of patients on phase III randomized controlled trials for locally advanced NSCLC is 61 years, 6 even though approximately half of the patients in the United States in whom lung cancer is diagnosed are older than 70. 7, 8 This raises concern about how applicable these trials are to older patients and poses a challenge for the oncologists who are managing the care of these patients. A large Surveillance, Epidemiology, and End ResultsMedicare analysis of patients older than age 66 with locally advanced NSCLC demonstrated that approximately one-third receive no treatment. 9 Even elderly patients with good performance status and lack of comorbidities are less likely than younger patients to be offered aggressive treatments on the basis of age. 10 Given the concern for decreasing functional reserve in older patients, providers question the elderly's ability to tolerate standard cancer treatments. 11 Although the elderly are no different than younger patients in their willingness to accept aggressive treatment, they are less likely to sacrifice quality of life for incremental improvements in survival. 12 However, there is a paucity of data to inform toxicity in the elderly population, perpetuating the phenomenon of ageism in cancer management.
Radiotherapy is a key component of the definitive treatment regimen for locally advanced NSCLC. Esophagitis and radiation pneumonitis are potentially lifealtering toxicities of thoracic radiation. There are limited data on the impact of age on incidence of these toxicities. We therefor, analyzed the association between age and radiation-induced toxicities in patients enrolled on our institutional prospective lung cancer protocols. We then sought to validate our results in an independent cohort of patients treated on a large observational study as part of a statewide radiation oncology consortium. We hypothesized that increasing age may predict higher rates of radiation-induced esophageal and pulmonary toxicity.
Methods

Primary Study Population
As part of an institutional review board-approved study, patients undergoing definitive radiation for lung cancer with or without chemotherapy from 2004-2013 were identified from a prospective institutional database in which patients of all ages were eligible for inclusion (the University of Michigan [UM] cohort). Patients were excluded if they were treated with stereotactic body radiation therapy (SBRT) or if complete dose-volume histograms (DVHs) were not available for review. Clinical records were reviewed to identify patient-and tumor-specific characteristics, including age, sex, smoking status, Karnofsky performance status (KPS), tumor histological subtype, tumor stage, and utilization of chemotherapy. Treatment plans were individually reviewed to collect actual dose received by the esophagus and lungs. All cases in the database utilized modern photon dose calculations (Analytical Anisotropic Algorithm [Varian Medical Systems, Palo Alto, CA]) and voxelbased biological corrections to equivalent dose in 2-Gy fractions (EQD2), using the linear quadratic model (a/ b ¼ 10 Gy for esophagus and a/b ¼ 3 Gy for lung), to account for variable dose per fraction prescriptions. All organs at risk were defined by using the Radiation Therapy Oncology Group Lung Atlas. 13 Esophageal dose was primarily defined as the minimum dose to the most exposed 2 cm 3 of the esophagus (D2cc), and lung dose was defined as the volume of both lungs not involved with gross disease that received at least 20 Gy, both of which have been previously correlated with toxicity. Secondary dosimetric parameters were generalized equivalent uniform dose (gEUD) with a ¼ 5 for the esophagus (a single dose value that is a biologically equivalent representation of the dose distribution across the organ) and mean dose for the lungs. As already noted, all dose values are in EQD2.
All patients had a toxicity evaluation by a radiation oncologist weekly during their radiation treatment. Follow-up schedules after completion of treatment varied; however, all patients were evaluated at least once in the first month after treatment, and every 3 months for the first 6 months. Physician-reported toxicity was collected at each of these visits and graded according to Common Terminology Criteria for Adverse Events, version 3.0, for esophagitis and pneumonitis. Maximum toxicity grade was used for this analysis.
Secondary Study Population
A second, independent cohort of patients with lung cancer was identified from the Michigan Radiation Oncology Quality Consortium registry (MROQC cohort).
MROQC is an alliance of 24 academic and community practice centers in the state of Michigan that is funded by Blue Cross Blue Shield of Michigan and through which clinical, treatment, and outcomes related data are prospectively collected for patients undergoing thoracic irradiation.
14 Each participating site submits DVHs and Digital Imaging and Communications in Medicineformatted files of actual treatment plans for each patient to MROQC. All patients undergoing definitive lung radiotherapy for stage I to III lung cancer were identified. Patients receiving SBRT and patients with incomplete DVHs were excluded. The same dose parameters for organs at risk identified in the derivative cohort were extracted from the MROQC database. EQD2 dose metrics were not available for this cohort so physical doses were used. MROQC eligibility is limited to patients undergoing conventional fractionation, and therefore, physical doses were thought to be comparable. Physician-reported toxicity was retrieved from weekly on-treatment visits during radiation and from follow-up visits.
Statistical Methodology
We fit a logistic regression separately to four outcomes (esophagitis or pulmonary toxicity, grade 2 or higher or grade 3 or higher) with the goal of accurately quantifying and validating the age-toxicity association. In addition to age and dose, we adjusted for potential confounders: chemotherapy utilization, smoking status (never, former, or current), and KPS. No variable selection was conducted. Descriptive summaries of the data (Figs. 1 and 2) suggested possible nonlinear age-toxicity and dose-toxicity relationships; however, after adjusting for other confounders, we did not find any nonlinear associations that could be supported in a cross-validated framework. Both chemotherapy use and smoking status exhibited "sparse data bias" (i.e., associations that were implausibly extreme on account of a combination of a relatively small toxicity rate and a limited sample size).
We adjusted for this bias by penalizing the likelihood with an expression equal to the log density of a normal distribution with variance equal to 2, thereby shrinking the estimated associations of chemotherapy and smoking status with toxicity toward their null value (OR ¼ 1). 15 
Results
There were 179 patients extracted for the UM cohort. After exclusions (26 for SBRT and 28 for incomplete DVH data), 125 patients with lung cancer were included in our analysis. The median age in our institutional database was 66, with 34% of the patients older than 70. Data from 708 patients were extracted for the MROQC cohort. Seventeen of these patients were missing information for one or more of the clinical prognostic covariates, leaving 691 analyzable patients. Patient characteristics are detailed in Table 1 .
Esophagitis
Among the 125 patients in the UM cohort, 49 (39%) and 14 (11%) experienced grade 2 or higher and grade 3 esophagitis, respectively. No grade 4 or 5 esophagitis was reported. Among the 82 patients younger than 70, these rates were 48% and 16%, respectively; among the 43 patients age 70 or older, they were 23% and 2%, respectively.
The multivariable regression models derived from the UM cohort for grade 2 or higher and grade 3 or higher esophagitis are given in columns 1 and 3 of Table 2 . In both models, there was a significant inverse correlation between age and incidence of esophagitis, with the odds of esophagitis reduced by a ratio of 0.92 to 0.93 for each additional year of age. The 95% confidence intervals (CIs) are similar: 0.87 to 0.97 and 0.86 to 0.99, respectively, for each model. Replacing D2cc with gEUD (a ¼ 5) and refitting these regression models yielded very similar results, with the ORs corresponding to age 
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being approximately 0.92, and the 95% CIs falling to less than 1. In Figure 3 D2cc is used to plot the model-estimated probabilities of grade 3 esophagitis by age for seven different dose values. These dose values represent equally spaced percentiles of the esophageal doses received by the 125 patients, spanning from 16 Gy (fifth percentile) to 75 Gy (95th percentile). At age 50, the probability of grade 3 or higher esophagitis ranges from approximately 0.1% at 16 Gy to 49% at 75 Gy. In contrast, by age 70, these probabilities fall to less than 0.1% at 16 Gy and 17% at 75 Gy. Thus, at very low and very high dose levels, the estimated relative risk for esophageal toxicity for a 70-year-old patient is onethird of that estimated for a 50-year-old.
The grade 2 or higher and grade 3 or higher esophagitis models for the UM cohort were cross-validated to assess model fit. The cohort was randomly partitioned into 10 subcohorts in a blocked fashion, meaning the patients experiencing esophagitis were distributed as uniformly as possible. We sequentially refit the model against all combinations of nine subcohorts, calculating the discrimination in the held-out subcohort. The average cross-validated discrimination values, or the areas under the receiver operating characteristic curve (AUCs), were 0.782 and 0.774, respectively, for grade 2 or higher and grade 3 or higher esophagitis. When these numbers are interpreted for a random pair of patients, one with esophagitis and one without, our model correctly identified the patient with esophagitis as having greater risk with a probability of 77%. The median cross-validated predicted probabilities of grade 2 or higher esophagitis were 58% and 32%, respectively, for patients who did and did not have grade 2 or higher esophagitis. For the grade 3 or higher model, these same probabilities were 23% and 6%, respectively. Among the 691 patients in the MROQC cohort with complete information, the numbers of patients with grades 2 or higher and or higher 3 or higher esophagitis were 356 (52%) and 13 (1.9%), respectively. One patient experienced grade 4 esophagitis, and no patients experienced grade 5 esophagitis. Among the 389 patients younger than 70, the rates of grades 2 or higher and 3 or higher esophagitis were 55% and 2.1%, respectively; among the 302 patients older than 70, these rates were 47% and 1.7%, respectively. The apparent inverse association between age and esophagitis was confirmed in the MROQC cohort after accounting for potential confounders, albeit to a lesser extent than in the UM cohort, with an OR of 0.97 to 0.98 per year. The 95% CIs were 0.96 to 0.99 and 0.92 to 1.03, respectively, for grades 2 or higher and 3 or higher esophagitis (Table 2) .
Radiation Pneumonitis
There was less evidence for an age-lung toxicity association. The rates of pneumonitis in the UM cohort were 32 of 125 (25%) and 11 of 125 (9%), respectively, for grades 2 or higher and 3 or higher. No patients experienced grade 4 pneumonitis, and two patients experienced grade 5 pneumonitis. Among the 83 patients younger than 70, the rates of grades 2 or higher and 3 or higher pneumonitis were 27% and 8%, respectively; among the 46 patients age 70 or older, these rates were nearly the same: 22% and 9%, respectively.
The multivariable regression models are given in Table 3 . There was no meaningful association between age and pneumonitis detected: OR ¼ 0.99 for grade 2 or higher and OR ¼ 1.02 for grade 3 or higher. The CIs are nearly symmetric, approximately 1 with a width of approximately 0.10. Replacing the volume of both lungs not involved with gross disease that received at least 20 Gy with the mean lung dose did not change our conclusions. Given that there was no association between pneumonitis and age, we did not seek to confirm this "lack of significance" in the MROQC cohort.
Discussion
Our study demonstrated a significantly decreased incidence of radiation esophagitis in elderly patients. This finding remained significant even after adjustment for esophageal dose, concurrent chemotherapy, history of smoking, and performance status. In patients who were never-smokers with good performance status and who received high doses of radiation to the esophagus with concurrent chemotherapy, the probability of esophagitis for a 70-year-old was approximately onethird that of an identical 50-year-old patient. This relationship between age and esophagitis was initially demonstrated in a prospective cohort from our institution and then validated in a large prospective statewide registry, suggesting generalizability to a broader population. The overall rate of grade 3 or higher esophagitis in the present study was 11% in the UM of the esophagus as a function of age for a hypothetical patient who is assumed to be a never-smoker with a Karnofsky performance status of 85 who is receiving concurrent chemotherapy. cohort, which is comparable to that in prospective randomized trials. 16 The overall rate of esophagitis was low in the MROQC cohort and may represent variations in toxicity reporting and grading among physicians. This lack of events could explain the attenuated trend in the MROQC database. In our analysis, there was no apparent correlation between radiation pneumonitis and age, which is consistent with prior studies. 17 Within this lack of correlation, it is still important to note that age did not appear to increase one's risk for pneumonitis.
To our knowledge, the inverse correlation between age and esophagitis is a novel finding in thoracic oncology. [17] [18] [19] [20] [21] Pignon et al. previously studied the effect of age on toxicity in patients undergoing thoracic radiation in a meta-analysis of six randomized trials. 17 Their study overall showed no significant agedependent distribution of acute or late toxicities. There was a trend toward increased late esophagitis in the elderly; however, this was attributed to a subset of patients who had undergone hypofractionated radiotherapy. Furthermore, the studies included in this meta-analysis used older radiation techniques. Our study is the first to evaluate the effect of age on toxicity related to thoracic radiotherapy in the context of dosimetric parameters in the modern treatment planning era, recognizing that dose itself is a significant confounder.
The main strength of our investigation is the large number of patients with prospectively collected toxicity data, as well as detailed dosimetric data for organs at risk available for correlation. For esophageal toxicity, we chose to look at D2cc, as several series have shown maximum doses to the esophagus to predict grade 3 esophagitis. [22] [23] [24] [25] Furthermore, using maximum dose reduces the impact of variations in esophageal contours. Although esophageal contours were standardized in the UM cohort, there are likely variations in the MROQC database. We also chose to look at gEUD, which allowed us to represent a heterogeneous dose distribution across a structure in terms of a single biologically equivalent dose value. We selected an "a" value of 5 for our gEUD calculation to give some weight to the maximum dose to respect the serial nature of the esophagus while incorporating volumetric dose. The ability to adjust for esophageal dose eliminates confounding factors related to tumor location, stage, and variations in treatment planning. We acknowledge that there are limitations to this study. The UM database comprises patients enrolled on institutional clinical protocols. Despite having no age limitations, physician assessment may bias which patients are offered enrollment. Most patients in the UM cohort had a KPS of 70 or higher, which may reflect a tendency to select fit patients for treatment. However, this was consistent in both younger and elderly patients. Given that our model was validated in a large independent cohort, undetected confounding factors are likely distributed homogenously. We recognize that chemotherapy is a significant contributor to esophagitis. In the UM cohort, most patients received concurrent chemotherapy. Furthermore, after adjustment for chemotherapy utilization, age remained a significant independent predictor of esophagitis. Further validation of these findings in a cohort in which all patients received full-dose chemotherapy and radiation may be warranted. Regardless, our data suggest that high doses of radiation with judicious use of chemotherapy are well tolerated in the elderly.
The mechanism behind decreased esophagitis in the elderly is not understood. We considered the possibility of decreased reporting in the elderly. However, there are objective surrogates for grade 3 esophagitis, including weight loss. Patients were weighed weekly, which we anticipated would identify patients with severely altered swallowing. We also analyzed median number of elapsed days during the treatment course to determine whether there was a tendency for older patients to take more treatment breaks or otherwise have a prolonged treatment course. However, we saw no differences between the patients older than and younger than 70. Esophagusspecific physiologic changes that would account for decreased effect from radiation were not found in our review of the literature. 26 There is, however, a body of evidence to suggest that there is decreased visceral pain sensation with advancing age. Lasch et al. used intraesophageal balloon distension to demonstrate significantly decreased esophageal pain sensation in healthy individuals older than 65 than in a younger population. 27 Johnson and Fennerty performed a population-based study of nearly 12,000 patients who were enrolled in clinical trials designed to assess the effectiveness of proton pump inhibitors in the setting of erosive esophagitis. 28 All patients reported their symptoms of heartburn at baseline and underwent an endoscopy to evaluate the status of esophagitis before any therapeutic interventions. Johnson and Fennerty found that patients older than 70 had the greatest incidence of severe esophagitis, yet were the least likely to report symptoms of severe heartburn. 28 These findings would suggest that older age is not necessarily protective against radiation-induced esophagitis, but rather that esophagitis is not readily detected in the elderly. Future study is required to understand the mechanism behind the decreased incidence of esophagitis in the elderly and the implications of this in their management.
Pattern of care studies suggest that the elderly are being undertreated for various malignancies, including lung cancer, independent of other variables, including performance status. 29, 30 Our study undermines this practice and supports standard definitive treatment for the elderly with good performance status.
